跳至主要内容
临床试验/NCT03033680
NCT03033680已完成1 期

Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA

Brigham and Women's Hospital1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2017年3月24日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
17
试验地点
1
主要终点
Tissue Volume of Distribution

研究概览

简要总结

The specific aims of the study are:

Primary: To determine the presence and regional distribution of microglial activation, as assessed by [F-18]PBR06 PET, in subjects with MSA as compared to healthy controls, at baseline and at 9 months follow-up.

Secondary:

To assess the relationship between microglial activation and clinical progression at baseline and follow-up.

Hypothesis: The working hypothesis is that there is microglial activation in Multiple System Atrophy and that the presence and regional distribution of microglial activation is different in MSA versus healthy controls and correlates with disease severity and comorbidities.

详细描述

Sixteen subjects with a probable MSA diagnosis will be recruited for this study. A probable MSA diagnosis will be based on the following criteria:

  • Autonomic failure involving urinary incontinence (inability to control the release of urine form the bladder, with erectile dysfunction in males) or an orthostatic decrease of blood pressure within 3 min of standing by at least 30 mmHg systolic or 15 mm Hg diastolic and
  • Poorly levodopa-responsive Parkinsonism (bradykinesia with rigidity, tremor, or postural instability) or
  • A cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction)

Summary:

Subjects will be recruited during routine clinical appointments by their physician or one of the other co-investigators listed on the protocol at the Movement Disorders Clinic, 60 Fenwood Road, Boston, MA. Once the subject gives the informed consent, investigators will be administering standardized questionnaires for assessment of disease severity, comorbidities and/or presence of symptoms, as applicable to a given cohort. In addition, a blood sample will be drawn for genotype testing to identify high affinity, medium affinity, and low affinity binders. Any subjects identified as low affinity binders will be excluded from the study.

Subjects will undergo two PET scans with [F-18]PBR06 at BWH PET scanning facility at 75 Francis Street, Boston, MA. For PET scanning, an intravenous (IV) catheter will be inserted for injection of tracer. In addition, prior to the tracer injection, a second IV catheter may be inserted into the other arm or hand vein on the contralateral side for blood sampling. To increase the usefulness of blood sampling for radiotracer analysis, the hand or arm used for blood sampling may be wrapped in an electrical warmer with the thermostat set at 44°C for approximately 5-10 minutes.The whole PET session will last approximately 120 min. At the time of imaging, the subjects will be positioned in the gantry of a PET camera. A head support will be used to minimize head motion.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Probable MSA clinical diagnosis.
  • Male and female subjects age 18 to 70 years.
  • Motor symptom onset <2 years prior.
  • Available brain MRI.

排除标准

  • Individuals with a known alternate neurologic disorder, previous head injury, or substance abuse.
  • Individuals with bipolar disease and schizophrenia
  • Concurrent medical conditions that contraindicate study procedures.
  • Women who are pregnant or nursing. Also, any woman who is seeking to become pregnant or suspects she is pregnant will be excluded from enrollment.
  • Claustrophobia
  • Corticosteroid treatment in the past four weeks
  • Non-MRI compatible implanted devices
  • Low Affinity binders

研究组 & 干预措施

Multiple System Atrophy (MSA)

Experimental

Eight subjects with a probable MSA diagnosis will be recruited for this study. Each subject will undergo a [F-18]PBR06 PET scan at baseline, and at 9 months follow-up.

干预措施: [F-18]PBR06 (Drug)

结局指标

主要结局

Tissue Volume of Distribution

时间窗: 1 month

PET imaging measurement

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Vikram Khurana

Assistant Professor of Neurology

Brigham and Women's Hospital

研究点 (1)

Loading locations...

相似试验